AbbVie has agreed to purchase Gilgamesh Pharmaceuticals’ investigational psychedelic drug candidate bretisilocin for up to $1.2 billion, including upfront and milestone payments. This acquisition underscores pharmaceutical giants' increasing commitment to psychedelic-based therapies, particularly for psychiatric conditions such as major depressive disorder. Gilgamesh will spin out its remaining assets into a new company. This deal follows a prior collaboration and significantly expands AbbVie's neuroscience pipeline, complementing its recent acquisition of Cerevel Therapeutics.